Understanding how to resolve inflammation to prevent cancer caused by toxic chemicals
Official title: Resolution of inflammation in chemical-induced cancer
Funded at Beth Israel Deaconess Medical Center · NIH-11046763 · Data updated 2026-11-12
This study is looking at how inflammation caused by harmful chemicals can lead to cancer and is exploring how certain natural substances in the body can help reduce inflammation without weakening the immune system, with the hope of finding better ways to treat cancer for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $749,474 |
| NIH project number | 1R01CA285395-01A1 |
| Project ID | NIH-11046763 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals exposed to toxic environmental chemicals who are at risk of developing cancer.
✕Less likely to help
Patients who have already been diagnosed with advanced cancer may not benefit from this research.
What this research studies
This research investigates the mechanisms behind how inflammation can lead to cancer when triggered by toxic environmental chemicals. It focuses on the role of specialized pro-resolving mediators (SPMs) that help clear inflammation without suppressing the immune system. By studying how these mediators can counteract the harmful effects of inflammation and prevent tumor growth, the research aims to develop new therapeutic strategies for cancer treatment. Patients may benefit from insights into how inflammation resolution can be harnessed to improve cancer therapies.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent cancer by promoting the resolution of inflammation.
How similar studies have gone: Other research has shown promise in using inflammation resolution strategies in cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Panigrahy, Dipak — Beth Israel Deaconess Medical Center
- Study coordinator: Panigrahy, Dipak
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.